How to buy Merus N-V stock - 19 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Merus N-V stock

Own Merus N-V stock in just a few minutes.

Merus N.V is a biotechnology business based in the US. Merus N-V shares (MRUS) are listed on the NASDAQ and all prices are listed in US Dollars. Merus N-V employs 87 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Merus N-V

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Merus N-V. Find the stock by name or ticker symbol: MRUS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Merus N-V reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Merus N-V, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Merus N-V. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Merus N-V share price

Use our graph to track the performance of MRUS stocks over time.

Merus N-V shares at a glance

Information last updated 2021-03-10.
52-week rangeUSD$10.18 - USD$31.27
50-day moving average USD$24.53
200-day moving average USD$17.05
Wall St. target priceUSD$24.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.94

Buy Merus N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Merus N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Merus N-V financials

Revenue TTM USD$28.7 million
Gross profit TTM USD$-24,547,000
Return on assets TTM -22.68%
Return on equity TTM -102.92%
Profit margin -288.92%
Book value $2.91
Market capitalisation USD$881.6 million

TTM: trailing 12 months

Shorting Merus N-V shares

There are currently 687,410 Merus N-V shares held short by investors – that's known as Merus N-V's "short interest". This figure is 2.3% down from 703,526 last month.

There are a few different ways that this level of interest in shorting Merus N-V shares can be evaluated.

Merus N-V's "short interest ratio" (SIR)

Merus N-V's "short interest ratio" (SIR) is the quantity of Merus N-V shares currently shorted divided by the average quantity of Merus N-V shares traded daily (recently around 249967.27272727). Merus N-V's SIR currently stands at 2.75. In other words for every 100,000 Merus N-V shares traded daily on the market, roughly 2750 shares are currently held short.

However Merus N-V's short interest can also be evaluated against the total number of Merus N-V shares, or, against the total number of tradable Merus N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merus N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Merus N-V shares in existence, roughly 20 shares are currently held short) or 0.0224% of the tradable shares (for every 100,000 tradable Merus N-V shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Merus N-V.

Find out more about how you can short Merus N-V stock.

Merus N-V share dividends

We're not expecting Merus N-V to pay a dividend over the next 12 months.

Merus N-V share price volatility

Over the last 12 months, Merus N-V's shares have ranged in value from as little as $10.18 up to $31.2712. A popular way to gauge a stock's volatility is its "beta".

MRUS.US volatility(beta: 0.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merus N-V's is 0.6949. This would suggest that Merus N-V's shares are less volatile than average (for this exchange).

Merus N-V overview

Merus N. V. , a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site